Galecto (GLTO) Stock Price

Galecto Price

NASDAQ·CLOSED
22.41
​
Market closed

The consensus 12-month price target for Galecto is 40.80 USD, about 82.1% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Galecto stock price

Access this data via the Eulerpool API

Galecto business model & stock analysis

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2020-10-29. The firm is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.

Frequently asked questions about Galecto

Analysts currently set an average price target of 41.48 USD for the Galecto stock (median: 40.80 USD), implying +85.1 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Galecto stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Galecto share trades at 20.00 EUR (22.41 USD).

The Galecto share (GLTO) is listed on 1 stock exchanges, including: NASDAQ (GLTO).

The revenue cannot currently be calculated for Galecto.

The expected profit of Galecto is -1.71 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Galecto is currently -20.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Galecto stock.

The P/S cannot be calculated for Galecto currently.

The Eulerpool Quality Score for Galecto is 2/10.

The ISIN of Galecto is US36322Q2066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Galecto is GLTO. The ticker symbol is used to trade Galecto shares on the stock exchange.

Fair ValueTerminal
19.94 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website galecto.com
Currency
USD
Initial public offering
Oct 29, 2020
ISIN
US36322Q2066
Cusip
36322Q107
Market capitalization
35.86 M USDMicro Cap
52-Week Range
PEG
-0.01
P/E ratio
P/Ee 2026
-20.91
P/Ee 2027
-10.84
P/Ee 2028
-8.94
P/Ee 2030
-9.29
P/S
P/Se
—
EV/EBIT
1.05
P/B Ratio
0.15
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-87.27 %
Last updated Oct 10, 2026, 3:59 PM

Galecto Peer Group

Galecto Ticker

NASDAQ · GLTO

All fundamentals and in-depth analysis of Galecto

Our stock analysis for Galecto stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Galecto. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.